Who are ABT-450/r/ABT-267, ABT-333's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/abt-450-r-abt-267-abt-333.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

ABT-450/r/ABT-267, ABT-333 — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

ABT-450/r/ABT-267, ABT-333 (ABT-450/r/ABT-267, ABT-333) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: HCV protease inhibitor and non-nucleoside polymerase inhibitor combination. Area: Virology / Hepatology.

phase 3 HCV protease inhibitor and non-nucleoside polymerase inhibitor combination HCV NS3/4A serine protease and NS5B RNA-dependent RNA polymerase Virology / Hepatology Small molecule Live · refreshed every 30 min

Target snapshot

ABT-450/r/ABT-267, ABT-333 (ABT-450/r/ABT-267, ABT-333) — AbbVie (prior sponsor, Abbott). This combination of hepatitis C virus (HCV) protease inhibitors and a non-nucleoside polymerase inhibitor blocks viral replication by inhibiting essential HCV enzymes.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
ABT-450/r/ABT-267, ABT-333 TARGET	ABT-450/r/ABT-267, ABT-333	AbbVie (prior sponsor, Abbott)	phase 3	HCV protease inhibitor and non-nucleoside polymerase inhibitor combination	HCV NS3/4A serine protease and NS5B RNA-dependent RNA polymerase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (HCV protease inhibitor and non-nucleoside polymerase inhibitor combination class)

AbbVie (prior sponsor, Abbott) · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ABT-450/r/ABT-267, ABT-333 — Competitive Intelligence Brief. https://druglandscape.com/ci/abt-450-r-abt-267-abt-333. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab